GLP-1 Weight-Loss Drugs Put $73 Billion in Global Food Brand Value at Risk, Report Finds

Approximately $6.8 billion of the brand value tied to Lay's potato chips is now structurally vulnerable to a shift in human metabolism. That figure, representing 45 percent of the brand's total $15.1 billion equity, makes the snack manufacturer the single most exposed food brand globally to the rising adoption of appetite-suppressing medications. The calculation arrives via a new analysis from the brand valuation consultancy Brand Finance, which attempted to put a hard financial number on a behavioral shift that has largely been discussed in qualitative terms. By assessing the world's 100 most valuable food brands, the firm determined that the pharmaceutical trend is no longer just a healthcare story, but a material headwind for the packaged food industry.[1][2]

Across those top 100 global food brands, which collectively hold $278 billion in value, the consultancy concluded that roughly a quarter of that total is now at risk. The $73 billion in exposed brand value is not distributed evenly across the grocery store; rather, it lands squarely on the center aisles. Confectionery, chocolate, and savory snacks account for 53 percent of the total brand value at risk in the analysis, despite representing just 30 percent of the overall brand value studied. The data underscores a disproportionate threat to indulgent food categories, as consumers utilizing the medications report a sharp decline in their desire for the calorie-dense products designed for mindless snacking.[1][2]

PepsiCo carries the most concentrated exposure of any single parent company in the analysis. Beyond Lay's, the corporation's five major snack brands collectively face $14.1 billion in vulnerability. The broader list of the most exposed brands reads like a roster of American vending machine staples, with seven of the top ten headquartered in the United States. Alongside the Frito-Lay portfolio properties like Doritos and Cheetos, the report identified Hershey's, Kellogg's, and Reese's as highly vulnerable to the shifting consumption patterns. These brands share a common profile: they are heavily reliant on impulse snacking occasions and indulgent formats, which are precisely the consumption moments that are currently under pressure.[1][2]

Henry Farr, the valuation director for Brand Finance, noted in a statement that the medications possess the potential to fundamentally redraw the competitive landscape for the entire food industry. The challenge for these legacy brands is that their core products are fundamentally at odds with the physiological effects of the drugs. GLP-1 medications, which include treatments originally developed for type 2 diabetes, operate by mimicking a naturally occurring hormone that stimulates insulin release and slows gastric emptying. The result is a prolonged feeling of fullness that directly suppresses the urge to eat between meals, effectively eliminating the primary use case for many savory snacks and confections.[1]

The financial quantification from Brand Finance follows a rapid and measurable acceleration in drug adoption over the past two years. According to a Gallup update published in September 2026, approximately 11 percent of adults in the United States currently take appetite-suppressing GLP-1 medications specifically for weight loss. That figure represents a near-quadrupling from the 3 percent recorded in 2024. With an estimated 137 million Americans—more than half of the adult population—now considered eligible for the drugs, the market for the treatments is expected to continue its steep upward trajectory, bringing downstream consequences for consumer spending.[1][2]

Those downstream effects are already materializing at the checkout counter, where the physiological changes induced by the drugs translate directly into altered purchasing behavior. While the Brand Finance report focused on brand equity, broader estimates suggest the total economic impact is even larger, with up to $149 billion in overall food spending potentially at risk. A recent study conducted by researchers at Cornell University found that overall grocery spending dropped by 6 percent in households containing at least one person taking weight-loss medications. The reduction in spending is driven by a stark decrease in daily intake; a July 2025 FAIR report observed that individuals using GLP-1 treatments consume an average of 700 fewer calories per day than they did prior to starting the regimen.[1][2][3]

Crucially for the snack industry, those missing 700 calories are not being subtracted evenly across all food groups. The FAIR report noted that GLP-1 users were most inclined to actively avoid processed foods, sugar-sweetened beverages, refined grains, and beef. Because the medications signal satiety to the brain, users frequently report a diminished interest in eating between meals. For companies whose business models rely heavily on impulse purchases and repeated daily snacking occasions, that physiological shift represents a structural threat that cannot be easily mitigated by traditional marketing strategies or minor product reformulations.[1][2]

The shifting landscape presents a strategic divergence for the food industry. While legacy snack brands face shrinking daily consumption, the broader market is seeing a pivot toward health-conscious, lower-calorie, and protein-forward product portfolios. The brands that successfully navigate the transition will likely be those that can adapt their offerings to align with the new metabolic realities of their customer base. As the adoption of appetite-suppressing medications continues to scale, the $73 billion in exposed brand value serves as a stark financial metric for an industry that must now account for a fundamental change in how the public eats.[1][2][4]